Shares of GENFIT S A/ADR (NASDAQ:GNFT) have been assigned an average recommendation of “Buy” from the seven brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $52.62.
Several brokerages have recently weighed in on GNFT. Roth Capital reiterated a “buy” rating on shares of GENFIT S A/ADR in a research report on Tuesday, April 23rd. Zacks Investment Research cut GENFIT S A/ADR from a “hold” rating to a “sell” rating in a research report on Tuesday, July 9th. Svb Leerink began coverage on GENFIT S A/ADR in a research report on Wednesday, April 24th. They issued an “outperform” rating and a $58.00 price target for the company. Stifel Nicolaus began coverage on GENFIT S A/ADR in a research report on Tuesday, June 25th. They issued a “hold” rating for the company. Finally, Barclays began coverage on GENFIT S A/ADR in a research report on Monday, April 22nd. They issued an “overweight” rating and a $55.00 price target for the company.
A number of hedge funds have recently modified their holdings of the business. Boussard & Gavaudan Investment Management LLP bought a new stake in GENFIT S A/ADR during the second quarter worth about $199,000. One68 Global Capital LLC bought a new stake in GENFIT S A/ADR during the first quarter worth about $270,000. TT International bought a new stake in GENFIT S A/ADR during the first quarter worth about $1,200,000. Dean Capital Investments Management LLC bought a new stake in GENFIT S A/ADR during the first quarter worth about $650,000. Finally, Victory Capital Management Inc. bought a new stake in GENFIT S A/ADR during the first quarter worth about $2,358,000. 14.69% of the stock is owned by hedge funds and other institutional investors.
About GENFIT S A/ADR
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.
Read More: What is Compound Annual Growth Rate (CAGR)?
Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with MarketBeat.com's FREE daily email newsletter.